Treatment of cutaneous leishmaniasis among travellers by Blum, J. et al.
Journal of Antimicrobial Chemotherapy (2004) 53, 158–166
DOI: 10.1093/jac/dkh058
Advance Access publication 16 January 2004
158
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
JAC vol.53 no.2 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
Treatment of cutaneous leishmaniasis among travellers
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Leishmaniasis is endemic in 88 countries on five continents. There are 1–1.5 million cases of cutaneous
leishmaniasis reported yearly worldwide. There has been a sharp increase in recorded cases over the last
10 years. Based on geographical distribution, cutaneous leishmaniasis is divided into Old World and New
World leishmaniasis. In the past, species could be inferred from geographical setting or determined by
performing culture and isoenzyme analysis. The recently developed and now widely available PCR tech-
nology allows a rapid diagnosis with determination of most species, and thus enables a species-orientated
treatment. While the Old World species mostly cause benign and often self-limiting cutaneous disease, the
American species cause a broad spectrum of conditions from benign to severe manifestations, including
mucosal involvement. The response to treatment varies according to the species. Therefore, a species-
specific approach is proposed. Drugs for systemic and topical treatment are presented and discussed with
regard to their application, use and adverse effects. Indications for local or systemic treatment are pro-
posed. Drugs under investigation are also mentioned. An overview of published treatment options and a
treatment recommendation is given for each of the most important species. The level of evidence of the studies
leading to these recommendations is given.
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Introduction
The large number of travellers from industrialized countries visiting
and increasingly enjoying outdoor activities in endemic areas are at
considerable risk of contracting cutaneous leishmaniasis. Most
physicians in industrialized countries have little experience with
cutaneous leishmaniasis in returning travellers. This often leads to
delayed diagnosis and inappropriate management. This review aims
to provide recommendations for the rational and effective treatment
of patients presenting with cutaneous leishmaniasis of various ori-
gins. Evidence-based data on travellers are limited to a few studies,
anecdotal reports and investigations among military personnel
deployed in endemic areas.1–3 It is therefore crucial to consider the
published experience among patients from endemic areas, even if the
immunological background will be different in an important part of
the respective study populations.4–6 Consequently, established treat-
ment schedules can be applied to all patients.
Leishmaniasis is endemic in 88 countries on five continents.
There are 1–1.5 million cases of cutaneous leishmaniasis reported
yearly among the local populations. The number of reported cases
has increased sharply over the last 10 years.7 The parasite is trans-
mitted by the bite of various types of phlebotomine sandflies.
Based on its geographical distribution, cutaneous leishmaniasis
can be divided into Old World (including southern Europe, the
Middle East, parts of south-west Asia and Africa) and New World
(from southern USA through Latin America to the highlands of
Argentina) leishmaniasis. Cutaneous leishmaniasis is caused by various
Leishmania species. While Old World species mostly cause benign
and often self-limiting cutaneous disease, New World species cause a
broad spectrum of conditions from benign to severe manifestations,
including mucosal involvement. The clinical spectrum of the disease
and its response to treatment vary according to the species. Therefore,
a species-specific approach should be considered.8 The traditional
method is to perform an isoenzyme analysis on Leishmania culture to
determine the species. Species can often be inferred from geographical
setting, thus adding to the accuracy of the diagnosis. In addition, the
recently developed PCR technology allows a rapid species-specific
diagnosis for most species.9 The introduction of this novel diagnostic
species differentiation using PCR methodology further contributes to
the possibility of a targeted, species-orientated treatment.
Treatment options: local versus systemic treatment
The proposed choice of local or systemic treatment of cutaneous
leishmaniasis (Table 1) is guided by the risk of developing mucosal
disease.
Mucosal leishmaniasis is mainly attributed to Leishmania brasil-
iensis, but is also described in Leishmania panamensis,10,11 Leishmania
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guyanensis12 and Leishmania amazonensis.13 Mucosal lesions were
found in Colombia among 19/397 (5%) patients with L. panamensis
and among 10/91 (11%) patients with L. brasiliensis infection.14 The
risk of late mucosal disease in cases due to L. brasiliensis has been
reported to be 2–10% among untreated cases.15,16 However, the
development of mucosal disease is subject to variation according to
place. Because published data do not allow the establishment of the
relative risk of mucosal disease for every species, systemic treatment
is proposed for all New World species, except for Leishmania mexi-
cana infection, where the risk of developing mucosal leishmaniasis is
almost zero.17 There is evidence that early systemic treatment may
prevent mucosal lesions, which are seen more frequently in patients
with incomplete or missing antimony treatment.15,16,18
Although mucosal lesions have been reported in Leishmania
donovani19 infections in Sudan, it is generally accepted to approach
Old World cutaneous leishmaniasis with local treatment.
Local treatment is applied in patients with a small, single lesion.
Based on expert opinion, systemic treatment is used in patients with
multiple lesions or large lesions (>5 cm). Systemic treatment is also
recommended in patients with metastatic spread and in cutaneous
lesions unresponsive to local treatment. Local treatment may be con-
sidered in patients for whom systemic treatment is contraindicated,
such as those who are pregnant or have cardiac problems.20
1. Systemic treatment (Table 2)
Pentavalent antimonials
The pentavalent antimonials meglumine antimonate (85 mg Sb/mL)
for intramuscular administration and sodium stibogluconate (100 mg
Sb/mL) for intravenous and intramuscular administration have been
used for decades for the treatment of New World cutaneous leishma-
niasis, and are the gold standard for other new investigational drugs.
The biochemical basis for their effectiveness is unknown, but may
involve inhibition of ATP synthesis. The drugs exist only in
parenteral forms. The dosage is usually given in Sb equivalents
(mg/kg/day). The pentavalent antimonials are far from being ideal
drugs because of their difficult administration and toxicity.3,21,22
Treatment schedules and dosages have been debated and changed
several times. In the 1980s, the dosage was increased from 10 to
20 mg/kg/day, with an upper limit of 850 mg/day (equivalent to two
ampoules of meglumine antimonate). The upper limit of 850 mg
Sb/day was abandoned in the early 1990s,22 since studies indicated a
reduced efficacy of lower doses and no higher toxicity was found
with the higher doses of the drug.1 However, the question of the
optimal dose has not yet been finally answered. The results of
trials in Brazil with lower doses have been published.23,24 A possible
disadvantage of low dosages and/or a short course of treatment is that
they could contribute to the appearance of resistance.
Pentamidine
Pentamidine, an aromatic diamidine, is toxic for a number of protozoa
and fungi including Leishmania, Pneumocystis carinii and African
trypanosomes. The mechanism of action has not been established.
Pentamidine is used as an alternative to the pentavalent anti-
monials, and is the first line treatment for cutaneous leishmaniasis in
French Guyana, where L. guyanensis is responsible for >90% of the
cases.6,25 A study in Colombia (with L. panamensis, L. brasiliensis
and L. mexicana) found that a short-course, low-dose regimen of
pentamidine isethionate had a similar cure rate (96%) to that of
meglumine antimonate (91%), with a similar rate of side effects.26,27
The short-course, low-dosage regimen of pentamidine in other-
wise healthy patients with cutaneous leishmaniasis was better toler-
ated than the higher dosages applied for Pneumocystis treatment in
HIV-positive patients: all adverse effects were reversible and no cases
of new diabetes mellitus were found among >2200 patients observed
with the low-dose regimen.6,25,26 However, the higher dosages
needed for the treatment of mucosal leishmaniasis (>2000 mg) may
cause diabetes mellitus.28 Blood sugar and glycaemia need to be
checked before every injection, because reversible glucosuria and
hyperglycaemia have been described after just one dose of penta-
midine 200 mg.29
Imidazoles/triazoles
The imidazoles and the structurally related triazoles were introduced
as antifungal drugs, but also have an antileishmanial activity. They
have the advantage of oral administration and few adverse effects,
but are only effective against some species (see species-specific
treatment below).
Itraconazole has also been used, but data are scarce and contro-
versial.
Fluconazole was studied in a randomized, double-blind, placebo-
controlled trial in Iran.30 It was well tolerated and showed promising
results in Leishmania major leishmaniasis (see below). Data on other
species of leishmaniasis are lacking.
Drugs under investigation
Miltefosine. Miltefosine, a phosphocholine analogue, showed high in
vitro activity against leishmania. The results of an uncontrolled trial
in Colombia (Phase I/II) are promising. Using doses of 133–150 mg/
day for 3–4 weeks, the per protocol cure rate (no parasites after
therapy, complete re-epithelialization after 3 months) was 94%.
However, a longer follow-up is needed to evaluate the relapse rate.
The most common side effects were motion sickness, gastrointestinal
complaints, headache and raised liver enzymes.31 Further controlled
studies with various species are needed before miltefosine can be
proposed as a routine treatment of cutaneous leishmaniasis.
Amphotericin B/liposomal amphotericin B. The antifungal agent
amphotericin B desoxycholate is active against Leishmania species,
but has the disadvantage of a high incidence of adverse reactions
(i.e. hyperpyrexia, severe malaise, hypotension, thrombophlebitis,
azotaemia, renal tubular damage, hypokalaemia, anaemia and hepa-
titis).
Several amphotericin B lipid formulations with much lowertoxic-
ities than the free drug have been developed, and have proved to be
Table 1. Proposed indications for local and systemic treatment
Proposed indications for local treatment
lack of risk of developing mucosal lesions
Old World cutaneous leishmaniasis
L. mexicana cutaneous leishmaniasis
small, single lesion
absence of lymph node metastasis
Proposed indications for systemic treatment
presence of mucosal lesion or lymph node metastasis
New World cutaneous leishmaniasis except L. mexicana lesions
lesions unresponsive to local treatment
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useful in the treatment of visceral leishmaniasis. Based on currently
available data, liposomal amphotericin B has been insufficiently
studied with regard to formulation and dosage to assess its efficacy in
cutaneous leishmaniasis.
Allopurinol. Allopurinol, an analogue of hypoxanthine, is generally
not effective in the absence of pentavalent antimony.32–35 However, a
combination of allopurinol (20 mg/kg/day for 15 days) and stiboglu-
conate (20 mg/kg/day for 15 days) was more effective in L. panamensis
(cure rate 71–74%) than stibogluconate alone at the same dose (cure
rate 36–39%).36,37
Drugs influencing the immune system. Immunomodulators represent
an interesting possibility for improving the cure rates of pentavalent
antimonials, but the lack of solid data does not allow respective
recommendations at present.
Other drugs. Other drugs, such as rifampicin,38 dapsone39 and oral
zinc sulphate,40 have been tested for leishmaniasis treatment. Some
are promising, but the results require confirmation before they can be
recommended for treatment.
2. Local treatment
Physical methods
Cutaneous leishmaniasis has been treated in patients of all ages with a
wide range of physical methods, including cauterization, surgical
excision, cryotherapy and the application of local heat. Cryotherapy
Table 2. Drugs and follow-up for treatment of cutaneous leishmaniasis
Drug Adverse effect Management/follow-up
Pentavalent antimonials cardiac toxicity with reversible ECG alterations is seen in 
30–60%: repolarization alterations affecting T wave and ST
 segment, prolongation of the corrected QT interval; fatal
 arrhythmias have not been documented with the usual dose 
of ≤20 mg Sb/kg22,76,77
ECG checks 1–2 every week; interruption of treatment 
if: (a) significant arrhythmias; (b) QTc longer than 
0.5 s (QTc longer than 0.45 s: monitoring/dose 
reduction); (c) concave ST segment
hepatotoxicity seen in 50%; reversible transaminases weekly; treatment interruption if 
transaminases >5× the upper limit of normal value 
(ULN)78
haematotoxicity (anaemia, leucopenia, thrombopenia)79 haemoglobin, leucocytes and platelets weekly 
hyperamylasaemia tended to occur very early in therapy and 
to decline despite continued treatment with antimonials
amylase daily during the first week, then twice 
weekly; treatment interruption if serum amylase 
levels became >4× the ULN or lipase levels >15× 
the ULN, regardless of symptoms; therapy can be
 resumed, once these values tend significantly 
towards normal3,80
subjective complaints: musculoskeletal symptoms, headache, 
gastrointestinal complaints, pain at the injection site
rare complications: glomerulonephritis, acute renal failure,81 
peripheral nephritis,82 exfoliate dermatitis, herpes zoster83
weekly examination of urine, creatinine
Pentamidine aseptic abscess (accidental contact of pentamidine with the 
subcutaneous tissue)
pentamidine has to be injected slowly and strictly 
intramuscular with a long needle (50 mm)
diabetes, hypoglycaemia, proteinuria fasting glycaemia and urine for proteinuria and 
gylcosuria have to be checked before every injection 
and 3 weeks and 2 months after the last injection84
hypotension6,26 blood pressure and heart rate have to be measured 
before and after the injection (every 15 min for 1 h)84
subjective complaints: myalgia, nausea and gustative 
abnormalities, headache, pain at the injection side, 
abdominal pain6
Ketoconazole hepatotoxicity reversible, usually mild54 transaminases weekly; treatment interruption if 
transaminases >5× ULN
diminution of testosterone values (70%), but without 
diminution of libido or beard growth54
reversible, no controls needed
subjective complaints: abdominal pain, headache, nausea, 
fever and malaise54
Fluconazole hepatotoxicity transaminases; treatment interruption if 
transaminases >5× ULN
allergic skin reactions
haematotoxicity (anaemia, leucopenia, thrombopenia) haemoglobin, leucocytes and platelets
subjective complaints: headache, gastrointestinal
complaints
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is performed by repeated topical applications of liquid nitrogen with a
cotton-tipped applicator or a cotton swab with moderate pressure to
the lesion, up to 2 mm outside the lesion margin. The freezing time
per application is 15–20 s. The procedure is repeated two or three
times at short intervals, resulting in a total time of 30–120 s. Adequate
application is reflected in the whitening of the skin at 2–3 mm outside
the margins of the lesion.41–44 The usual post-freeze pattern is some
oedema and blistering of the lesion itself for 2–3 days, followed by
crusting and formation of an eschar.41,42
Uncontrolled studies in Old World leishmaniasis, which did not
mention the species, gave cures rates of close to 100% after one to
three sessions of cryotherapy in Egypt (30/30 patients with clinical
and parasitological cure within 4–5 weeks),41 Jordan (effective and
significant clinical response in 214/215 patients within an undeter-
mined time)43 and Israel (complete clinical healing in 40 lesions in
14 patients within 3–8 weeks).42
However, in a comparative, non-randomized study from Turkey,
the cure rates (complete healing and disappearance of all clinical
features) after one or two sessions of cryotherapy were 77% (46/60)
after 1 month and 73% (44/60) after 3 months, compared with 85%
after 1 and 3 months following intralesional sodium stibogluconate.44
In an uncontrolled study in Iraq, two sessions with local heat (55°C
over 5 min) provided by an infrared lamp and focused on the lesion
gave a cure of 177/178 lesions (no species determination per-
formed).45
However, practical experience with local heat from an infrared
lamp shows that healing of the lesion was almost invariably accom-
panied by a heat-induced skin bulla.
Ointment containing 15% paromomycin
Topical formulations offer significant advantages over systemic
therapy, such as ease of administration, fewer adverse effects and
cost effectiveness. However, percutaneous absorption is hampered
by the intact skin, mainly in the stratum corneum. Topical applica-
tions may be applied to open lesions that have lost their stratum
corneum barrier property, but are less successful in lesions where
absorption is hindered by epithelial thickening.
Paromomycin, an aminoglycoside antibiotic (identical to amino-
sidine) has been used systemically against both visceral and cutan-
eous leishmaniasis. As an ointment for topical use, it has been tested
in different formulations, either with methylbenzethonium in white
soft paraffin, or with urea and white soft paraffin.
The combination of paromomycin with methylbenzethonium
appears to be more effective than the combination with urea, but it
causes more local inflammatory reactions.46 With New World leish-
maniasis, however, experts are hesitant to treat cutaneous lesions top-
ically because of the risk of mucosal disease, although this ointment
was reported to have much better cure rates than placebo in two stud-
ies.47,48
Local infiltration with pentavalent antimony
Local infiltration of lesions with pentavalent antimony produces the
maximum concentration in the lesions and has few systemic side
effects, but does not reach metastatic infections. The basic aim is to
fill the infected part of the dermis with pentavalent antimony. This
means carefully infiltrating the area around the lesion, including the
base of the lesion. A fine gauge (25G) needle is used to inject the drug
under pressure as the needle advances. Injection into the dermis is
difficult, as the tissue space is small. The drug must not be injected
into the subcutaneous tissue, where it is rapidly absorbed and does not
reach the site of infection.
The infiltration is performed in a V-shaped pattern, advancing the
needle into the base of the lesion (see Figure 1). The solution is
injected under the edges of the lesion and the entire lesion until the
surface has blanched. Treatment should be given every 5–7 days, a
total of two to five times. If the lesion is not healing after five treat-
ments, it should be reviewed in 1 month, when a decision about
reverting to systemic treatment should be made.49 Intralesional infil-
tration is painful and requires some experience to perform.50
Species-specific therapy (Table 3)
(A) New World leishmaniasis
L. mexicana: local treatment. Strains of L. mexicana isolated from
Belizean patients were found to be highly susceptible to paromo-
mycin sulphate both in vitro and in animal studies.51 An ointment
with 15% paromomycin/12% methylbenzethonium chloride applied
twice daily over 20 days was used in Guatemala and in Belize, where
L. brasiliensis and L. mexicana are endemic. In Guatemala, the final
clinical response rate at the 12 months follow-up examination was
higher in the treatment group (31/35, 88.6%) than in the placebo
group (13/33, 39.4%) (P ≤ 0.001).47 In Belize, the cure rate of 53
patients was 74%.52
L. mexicana: systemic treatment. Ketoconazole (600 mg daily for
28 days) was compared with sodium stibogluconate in patients with
cutaneous leishmaniasis in Guatemala. The outcome was related
to the species. Whereas ketoconazole had a higher cure rate for
L. mexicana (8/9 versus 4/7), the response rate in L. brasiliensis was
much lower (7/23 versus 24/25).53
Considering the virtually non-existant risk of mucosal leishmaniasis
with L. mexicana infection, 15% paromomycin/12% methylbenze-
thonium ointment is recommended as the first-line treatment. Where
it is not available, infiltration with glucantime may be an easily acces-
sible option, although no firm data have been published. Systemic
Figure 1. Procedure for intralesional treatment with pentavalent antimony (from
reference 25). Reproduced with permission from WHO.
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treatment with ketoconazole is another documented option. The
choice depends on the clinical aspect of the lesion (see above).
L. panamensis: local treatment. The 1 year cure rate with a 15% paro-
momycin/12% methylbenzethonium chloride ointment was 85% in
52 Ecuadorian patients, compared with 9% in a non-randomized
untreated control group.48 Nevertheless, experts are reluctant to
apply local treatment because of the risk of mucosal leishmaniasis.
L. panamensis: systemic treatment. (i) Ketoconazole. In a ran-
domized clinical trial, ketoconazole (600 mg daily for 28 days) had a
similar efficacy (16/21, 76%) to sodium stibogluconate (20 mg/kg/day
with upper limit of 850 mg, resulting in 13 mg/kg/day) (13/19, 68%),
but a much better efficacy than placebo (0/11).54 (ii) Pentavalent
antimonials. The response to antimonials is dose dependent: patients
treated with 10–13 mg/kg/day1,54 had cure rates of only 68–72%,
whereas patients treated with 20 mg/kg/day for 20 days had a
96–100% cure rate.1
The optimal duration of treatment with the dose of 20 mg/kg/day is
still debated. Whereas some authors regard a 10 day course of treat-
ment to be sufficient,2 and equal to a 20 day regimen,5 other studies
indicate a clear positive correlation between treatment duration and
efficacy: in one study the cure rates were 20% for 3 days, 53% for
7 days and 84% for 20 days treatment duration.55
In Guatemala, a surprisingly insufficient response (36–39%) to a
15 day course of pentavalent antimonials could be improved to
71–74% by the addition of allopurinol (20 mg/kg/day/15 days, given
in four divided doses).36,37 This combination was not compared with
the usual 20 day course of stibogluconate. However, the addition of
allopurinol to stibogluconate provided no clinical benefit in patients
with mucosal leishmaniasis.56
Considering the oral application and the lower rate of side effects
with ketoconazole, it can be recommended as the first choice for
uncomplicated lesions (i.e. not multiple, not long-lasting lesions,
with no sign of mucosal involvement), especially when a close clin-
ical follow-up and patient compliance are guaranteed. Pentavalent
antimonials are used if the response to ketoconazole is not satisfac-
tory. Either a 20 day course or the combination with allopurinol is
recommended.
L. guyanensis. There are only a few, non-randomized trials concerning
the optimal treatment of L. guyanensis. The cure rate (6 months) of
antimonials (20 mg Sb/kg/day for 20 days) was significantly lower in
patients infected with L. guyanensis (26.3%) than in patients infected
with L. brasiliensis (50.8%; P = 0.003).57 In French Guyana, where
L. guyanensis is responsible for >90% of cutaneous leishmaniasis,
a short-course regimen of pentamidine is the first-line treatment.
The cure rates are dose dependent (600 mg, 73%; 900 mg, 90%;
8 mg/kg/day, 90%). A total dose of 1200 mg was proposed.25 Two
injections with 4 mg/kg/day had a cure rate of 89%. Patients with sat-
ellite papules or more than three lesions were at a relatively high risk
of not being cured. A second treatment with the same dosage had a
cure rate of 80%.6 These doses were in the same range as the dosages
proposed by Soto in Columbia (i.e. pentamidine isethionate given in
four injections of each 3 mg/kg/day every other day).26,27
Considering the poor response to pentavalent antimonials and the
good experience in French Guyana, pentamidine is recommended as
the first choice, in a dosage of four injections containing 3 mg/kg/day
every other day. Local treatment is not recommended due to a lack of
sound data.
L. brasiliensis. Because of the high risk of late mucosal disease in
infections with L. brasiliensis, systemic treatment with pentavalent
antimonials (Sb 20 mg/kg/day for 20 days) is the gold stand-
ard.3,15,16,22,58 The cure rates found in various studies range from low
(50%)57,59 to excellent (96–100%).2,21,53 Different study sites and
strains as well as different patient selection may contribute to these
varying findings.57
Studies with lower doses gave controversial results. In Guate-
mala, a shorter course with only 15 mg/kg/day over 14 days gave a
final cure rate of 64%,60 whereas studies from the state of Rio de
Janeiro (Brazil) indicated that lower dosages gave similar results to
higher doses. Oliveira-Neto et al.24 compared a low-dose regimen
(Sb 5 mg/kg/day for 30 days) with the conventional dosage of Sb
20 mg/kg/day. The cure rates were similar in the two groups (10/12
versus 9/11) after 30 days, with a lower toxicity in the lower dosage
group.24 Oliveira-Neto et al.23 treated 156 patients with the lower
dose; 84% were cured and did not develop mucosal disease or relapse
during an observation period of 5–10 years. However, the authors
concluded that although this low-dose regimen is adequate for this
particular endemic region, it should not be applied without confirma-
tion in other endemic settings.
The diversity of L. brasiliensis susceptibility to pentavalent anti-
monials means that the chance of a favourable treatment response can
not be evaluated in the individual traveller. Therefore, the current
recommendation to give pentavalent antimonials at the dosage of
20 mg/kg/day for 20 days is maintained.22,58 Poor clinical response in
some studies raises the question of antimonial resistance; however,
there is no published evidence to date to confirm true resistance in
cutaneous leishmaniasis.
Other species. Data on the treatment of other species of New World
cutaneous leishmaniasis like L. amazonensis, Leishmania venezuel-
ensis or Leishmania peruviana are scarce. Therefore, the current
recommendation of pentavalent antimonials at the dosage of
20 mg/kg/day for 20 days is still valid.22,50,58
(B) Old World leishmaniasis
L. major. The risk of metastatic lesions, including mucosal leishma-
niasis, is almost zero, except for L. donovani in Sudan, and local treat-
ment is often used.
An ointment containing 15% paromomycin and 12% methyl-
benzethonium chloride (applied twice daily for 10 days) was more
effective than placebo in L. major cutaneous leishmaniasis (cure 29/
39 versus 4/15).61 The parasitological cure rate for the same ointment
was 72% (48/67) after 10 days. After an additional 20 days, the
rate was 87% (58/67).62 Apart from local inflammation and pain, the
ointment was well tolerated. The use of 15% paromomycin/12%
urea ointment in two randomized, placebo-controlled studies on
L. major in Iran63 and Tunisia64 could not demonstrate any clinical
benefit, even though there was a significant parasitological response
at day 15 in the Iran study.
Local infiltration with antimonials (sodium stibogluconate
100 mg/mL 0.3–3 mL/lesion or meglumine antimonate 0.2–0.8 mL/
lesion) was studied in Saudi Arabia in regions where L. major and
Leishmania tropica are endemic, and where lesions of acute leish-
maniasis often heal spontaneously within 7–12 months. Two to 15
infiltrations (from all sides, until the lesion has blanched) were
needed to achieve cure rates of 72–99%.65–67
In a randomized, double-blind, placebo-controlled trial in Iran,
fluconazole 200 mg daily for 6 weeks showed promising results.
Healing of lesions was complete for 63/80 (79%) at the 3 months
follow-up in the fluconazole group, but only in 22/65 (34%) in the
Review
163
placebo group.30 Ketoconazole is less well studied, but appeared to be
effective in L. major in Israel. The cure rate was 70% after 200–400 mg
daily for 4–6 weeks.68,69 Pentavalent antimonials were efficient in six
patients with a dose of 20 mg/kg/day over 10–20 days,2 and are an
alternative in cases of treatment failure.
An ointment containing 15% paromomycin and 12% methyl-
benzethonium chloride, intralesional pentavalent antimonials and
thermotherapy (see above) are possible first choices in this usually
self-limiting disease, although these different treatment options have
rarely been tested against one another. The choice between them
depends on the experience of the treating physician and the avail-
ability of the method. If systemic treatment is indicated, fluconazole
or ketoconazole is recommended.
L. tropica/Leishmania infantum. There are no randomized, double-
blind, placebo-controlled clinical studies for treatment of these species.
Table 3. Treatment by species
aLevel of evidence: recommendation grade. (A) Randomized, controlled trial in representative collective. (B) Randomized, controlled trial in partially repre-
sentative (small patient number, different species included) collective. Cohort trial or case control study in representative collective. (C) Cohort trial or case–
control study in partially representative collective, series of cases in representative collective. (D) Series of cases in partially representative (small patient
number, different species included) collective, informal expert opinion, other information.
Species Drug Dosage
Level of 
evidencea
L. mexicana local: ointment: 15% paromomycin plus 12% 
methylbenzethonium chloride
twice daily for 20 days B47,52
ketoconazole 600 mg daily for 28 days B53
L. panamensis ketoconazole 600 mg daily for 28 days A54
pentavalent antimonials 20 mg Sb/kg/day for 20 days A1,2
pentavalent antimonials and in addition allopurinol 20 mg Sb/kg/day for 15 days A36,37
20 mg/kg/day given in four doses for 
15 days
L. guyanensis pentamidine isethionate four injections of 3 mg/kg/day every 
other day
C6,25
L. brasiliensis pentavalent antimonials 20 mg Sb/kg/day for 20 days A22,53,58
L. major 15% paromomycin/12% methylbenzethonium 
chloride ointment
twice daily for 10–20 days A61,62
localized heat or cryotherapy two sessions with localized heat (55°C 
for 5 min)
C45
two to three sessions of topical application 
of liquid nitrogen
C41–43
local infiltration with antimonials sodium stibogluconate, meglumine 
antimonate
A65–67
complete blanching of lesion has to be 
achieved
upper limit 5 mL per infiltration and 20 mg 
Sb/kg
once or twice weekly
one to five infiltrations
fluconazole 200 mg daily for 6 weeks A30
L. tropica/L. infantum local infiltration with antimonials sodium stibogluconate, meglumine 
antimonate
D
complete blanching of lesion has to be 
achieved
upper limit 5 mL per infiltration and 20 mg 
Sb/kg
once to twice weekly
one to five infiltrations
15% paromomycin/12% methylbenzethonium 
chloride ointment
twice daily for 10–20 days D
cryotherapy or localized heat two to three sessions of topical application of 
liquid nitrogen; two sessions with localized 
heat (55°C for 5 min)
C41–43, D
pentavalent antimonials 20 mg Sb/kg/day for 10–20 days D
fluconazole 200 mg daily for 6 weeks D
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According to estimates made by the WHO, 90% of L. tropica
lesions in Pakistan could be healed by intralesional pentavalent anti-
monials.49 This treatment gave cure rates of 72–99% in Saudi Arabia,
where L. tropica and L. major are endemic (see above).65–67
However, recent experience in Israel, using PCR for species-
specific diagnosis,70 showed recurrent failure of local paromomycin
and intralesional sodium stibogluconate treatment against L. tropica,
and a good response to 10 days of systemic sodium stibogluconate
treatment (E. Schwartz, unpublished results). In studies using keto-
conazole, L. tropica appeared to be less responsive than L. major.68
In India, a 10 week course of ketoconazole 400 mg/day was ineffect-
ive in patients with L. tropica lesions.71,72
Anecdotal reports have shown a therapeutic response of
L. infantum lesions to intralesionally injected N-methylglucamine.73
Thermotherapy, intralesional pentavalent antimonials and oint-
ments are possible first choices in this usually self-limiting disease.
Again, the choice depends on the experience of the treating physician
and the availability of the method.
The role of fluconazole in the treatment of L. infantum and L. tropica
has not yet been established.
Clinical experience has shown that pentavalent antimonials are
effective in severe infections with big or multiple lesions on the face
or over the joints.2
Management issues: clinical follow-up and treatment 
failure
Cutaneous leishmaniasis lesions may demonstrate only a partial clin-
ical response after 3–4 weeks, and may not completely heal until
several weeks after completion of treatment. Therefore, patients
should be re-evaluated 4–6 weeks after the completion of treatment.
In patients with New World cutaneous leishmaniasis, manage-
ment is more complicated, since in most cases systemic treatment is
warranted. The treatment of choice is pentavalent antimonials, which
require meticulous follow-up because of the potential for adverse
events (see Table 2). Thus, in many centres these patients are treated
in hospital, although some authors have had good experience with
ambulatory care.21
The most common and worrisome laboratory abnormalities are
elevated liver enzymes and asymptomatic hyperamylasaemia. We
usually continue treatment if liver enzymes are below five times the
normal range and amylase less than five times the normal range
(Table 2). Interestingly, by decreasing the dose or interrupting treat-
ment for several days, the abnormal values go back towards normal,
and after reinstitution of the drug, the abnormal laboratory findings
may not recur.74
Relapse may occur several months after complete cure. It is
important to distinguish between clinical and parasitological healing.
Despite clinical healing of a lesion, PCR can remain positive several
years later.75
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